newsfilter
← Latest News
PR Newswire·

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

  • Theravance Biopharma, Inc. will report third quarter 2025 financial results & provide a business update after market close on Monday, November 10, 2025.
  • A conference call & simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST / 10:00 pm GMT) on that date.
  • Pre-registration is required for telephone participation, while the webcast is accessible via the company's website or Events and Presentation page.
  • A replay of the webcast will remain available on the website for 30 days through December 10, 2025.
  • The company's FDA-approved product YUPELRI (revefenacin) is indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD).
  • Ampreloxetine, a late-stage investigational norepinephrine reuptake inhibitor, is being developed for symptomatic neurogenic orthostatic hypotension in Multiple System Atrophy patients.